Oxford, UK and Marlborough, MA; January 7th 2010 – Oxford Immunotec Ltd, the world leading manufacturer and marketer of T Cell based diagnostic tests, has today announced the election of Dr. Peter Klemm, President and CEO of Predictive Biosciences, as a Non-Executive Director and the appointment of Frank Vandeputte as Vice President, Sales and Marketing.
Peter Klemm, Ph.D.
Non-executive director
Dr. Klemm is the former Chief Executive Officer of GeneOhm Sciences, a molecular diagnostics company pioneering the rapid detection of bacterial organisms, including those known to cause hospital acquired infections (HAIs). He led GeneOhm from its early days to the company’s acquisition by Becton Dickinson in February 2006 for $230 million. Prior to that Dr. Klemm was CEO of JOMED Inc., a Swiss-based company that develops and manufactures products for interventional cardiology, radiology and minimally invasive vascular surgery. He is currently the CEO of Predictive Biosciences, a molecular diagnostics company headquartered in Lexington, MA which focuses on non-invasive diagnostics for the management of cancer. Commenting on his appointment, Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec said, “I am delighted that Peter has agreed to join our board. His first-hand experience of building successful highvalue diagnostics companies will be invaluable in guiding the continued growth of the Company.”
“I am very pleased to be joining the Board of Oxford Immunotec,” said Dr. Klemm “Oxford Immunotec is a rapidly emerging diagnostics company with a talented management team and very interesting product and pipeline. I look forward to working with the management and the Board to support the growth of the company.”
Frank Vandeputte,
Vice President, Sales and Marketing
Mr. Frank Vandeputte is the former VP, Europe for CryoCath Technologies Inc. (TSX:CYT), a medical technology company focusing on cryotherapy products to treat cardiac arrhythmias. Heading the European business operation, Mr Vandeputte was responsible for developing and implementing strategic and operational business plans with the objective of driving rapid sales growth in the European market and led the European team though the company’s acquisition by Medtronic in November 2008. Prior to CryoCath, he served as VP, International Marketing and subsequently Area VP, Benelux and Nordic for the Sorin Group. With over 20 years experience in the medical device industry, Mr Vandeputte has held senior management positions with leading companies, including Baxter International Inc, Becton Dickinson and Guidant Corporation.
Commenting on his appointment Dr Peter Wrighton-Smith said, “Frank’s experience in changing medical practice and building new markets for innovative technologies that improve patient care whilst being costeffective for healthcare systems will be a great asset to the Company. I look forward to his leadership of our EMEA sales and marketing team”
About Oxford Immunotec
www.oxfordimmunotec.com
Oxford Immunotec Ltd., the T cell measurement company, is headquartered near Oxford, UK; its US operations are based in Marlborough, MA. The company develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first FDA-approved method for directly quantifying antigenspecific T cells.
T-SPOT technology is a simple and extremely accurate method of studying a person’s cellular immune response to infection and could be applied to diagnose and monitor any major disease driven by a T cell response.
About T-SPOT®.TB test
The T-SPOT.TB test is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and is the first product from Oxford Immunotec using T-SPOT technology. The product offers unrivalled sensitivity with results unaffected by a patient’s immune status. The T-SPOT.TB test is approved for sale in Europe, USA, Canada and over 40 other countries worldwide and is designed to replace the 115 year old tuberculin skin test. It offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market exceeding $1bn.
